When FDA finds that a manufacturer has significantly violated FDA regulations, FDA notifies the manufacturer. This notification is often in the form of a Warning Letter. The Warning Letter identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use. The letter also makes clear that the company must correct the problem and provides directions and a timeframe for the company to inform FDA of its plans for correction. FDA then checks to ensure that the company’s corrections are adequate. Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.
The issuing office in FDA warning represents the division of the FDA that released the warning letter. A common focus in the pharmaceutical industry is CDER (Center for Drug Evaluation and Research). Although not solely, this is a key division for FDA warning letters regarding drugs.
FDA warning letters usually result after a failed response to an inspection with observations. Althought it is not possible to predict warning letters. Following site inspections on Wizmed and watching 438s is a good way to see who many continue to escalate to a warning letter. If you would rather lookup all data sources at once you can use one search and here are those results for meropenem .Recent FDA 483s